Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications.
Spalato-Ceruso M, Laroche-Clary A, Perret R, Valverde Y, Chaire V, Derieppe MA, Velasco V, Bourdon A, Italiano A. Spalato-Ceruso M, et al. Among authors: velasco v. Exp Hematol Oncol. 2023 May 31;12(1):51. doi: 10.1186/s40164-023-00416-z. Exp Hematol Oncol. 2023. PMID: 37259134 Free PMC article.
CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.
Laroche-Clary A, Lucchesi C, Rey C, Verbeke S, Bourdon A, Chaire V, Algéo MP, Cousin S, Toulmonde M, Vélasco V, Shutzman J, Savina A, Le Loarer F, Italiano A. Laroche-Clary A, et al. Among authors: velasco v. Ann Oncol. 2018 Apr 1;29(4):1023-1029. doi: 10.1093/annonc/mdy039. Ann Oncol. 2018. PMID: 29409053 Free article. Clinical Trial.
IDO Targeting in Sarcoma: Biological and Clinical Implications.
Nafia I, Toulmonde M, Bortolotto D, Chaibi A, Bodet D, Rey C, Velasco V, Larmonier CB, Cerf L, Adam J, Le Loarer F, Savina A, Bessede A, Italiano A. Nafia I, et al. Among authors: velasco v. Front Immunol. 2020 Mar 5;11:274. doi: 10.3389/fimmu.2020.00274. eCollection 2020. Front Immunol. 2020. PMID: 32194552 Free PMC article.
LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications.
Ben-Ami E, Perret R, Huang Y, Courgeon F, Gokhale PC, Laroche-Clary A, Eschle BK, Velasco V, Le Loarer F, Algeo MP, Purcell J, Demetri GD, Italiano A. Ben-Ami E, et al. Among authors: velasco v. Cancers (Basel). 2020 Mar 23;12(3):757. doi: 10.3390/cancers12030757. Cancers (Basel). 2020. PMID: 32210091 Free PMC article.
Superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor are overlapping entities: a comprehensive study of 20 cases.
Perret R, Michal M, Carr RA, Velasco V, Švajdler M, Karanian M, Meurgey A, Paindavoine S, Soubeyran I, Coindre JM, Boidot R, Charon-Barra C, Geneste D, Weingertner N, Pissaloux D, Tirode F, Baud J, Le Loarer F. Perret R, et al. Among authors: velasco v. Histopathology. 2021 Nov;79(5):810-825. doi: 10.1111/his.14429. Epub 2021 Sep 5. Histopathology. 2021. PMID: 34121219
GSK3-beta as a candidate therapeutic target in soft tissue sarcomas.
Verbeke S, Perret R, Chaire V, Richard E, Velasco V, Giles F, Cavalcante L, Italiano A. Verbeke S, et al. Among authors: velasco v. J Hematol Oncol. 2021 Dec 2;14(1):202. doi: 10.1186/s13045-021-01215-x. J Hematol Oncol. 2021. PMID: 34857030 Free PMC article.
Giant Cell Tumors With HMGA2::NCOR2 Fusion : Clinicopathologic, Molecular, and Epigenetic Study of a Distinct Entity.
Perret R, Malaka Z, Velasco V, Llamas-Gutierrez F, Ropars M, Linck PA, Hostein I, Azmani R, Valo I, Galmiche L, Moreau A, de Pinieux G, Michot A, Bochaton D, Coindre JM, Le Loarer F. Perret R, et al. Among authors: velasco v. Am J Surg Pathol. 2023 Jul 1;47(7):801-811. doi: 10.1097/PAS.0000000000002051. Epub 2023 May 12. Am J Surg Pathol. 2023. PMID: 37170907
224 results